The biologic segment is widely recognised as the fastest growing within the pharmaceutical industry, consistently outpacing small molecule drugs in sales growth and market expansion. The biologics market is projected to experience a double-digit (+15 percent) compound annual growth rate (CAGR) until 2027 (source: IQVIA and Stevanato Group internal analysis).
In addition to market growth, biological drugs are increasingly complex and sensitive, while product quality requirements are becoming ever more stringent.
To meet the increasingly demanding requirements of biologic drugs—such as sensitivity to packaging materials, precise dosing and compatibility with complex delivery systems—primary packaging must evolve accordingly.
Stevanato Group’s proprietary glass converting technology is specifically designed to address these challenges, ensuring that biologic formulations are safely contained and effectively delivered:
Extended 100 percent forming temperature control by pyrometers- Monitoring of forming speed (rotation and tool speed)
- 100 percent advanced inline dimensional control systems for the most critical and/or crucial dimensions and statistical in-process controls
- Optimised tool design and use of new materials for improved handling of the containers
- 100 percent online camera inspection for cosmetic defects
Full control over the forming process and continuous product improvements lead to an optimisation of the internal shape, resulting in maximum dosing accuracy. In addition, this enables Stevanato Group to ensure high glass strength against external influences impacting the primary packaging, such as in drug delivery systems.
Stevanato Group develops its lines with an emphasis on all stages of forming, including the feeding of glass tubes, the glass forming process, transport, annealing and packing, and manufactures primary containers that meet different market needs.
Outstanding Glass Container Platforms
Fina®, Nexa®, Alba® are the Stevanato Group primary packaging product lines. All ensure improved mechanical strength, excellent cosmetic appearance, tight dimensional tolerances, consistent surface performance, and maximum compatibility with drug delivery devices.
These platforms are designed to meet the specific challenges of biologic drug containment, offering tailored solutions for different sensitivity levels and delivery requirements, including the delivery of higher-volume and viscous drugs.
Alba®, Nexa®, Fina® platforms are all available in EZ-fill® configuration; ready-to-use solutions that reduce total cost of ownership and time to market, preserving quality and increasing flexibility.